Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$32.71
▼ $0.14 (-0.4%)
Market data updated: 09/20 06:52 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$2.06B
Day Range
$31.54 - $32.80
52-Week Range
$9.80 - $47.84
Beta
—
Next Earnings
11.11.2026
Support
$31.54
Resistance
$46.87
KOD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+232.4% (1Y)
Strengths: 2/23 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 4.72
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$47.86 vs. price $32.71 (-246.3%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
35
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
No data available
Value
38
Momentum
6
Risk
48
Sentiment
80
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Kodiak Sciences is highlighted for its three imminent Phase 3 readouts across eye‑disease programs, which are seen as decisive for its stock. Recent coverage also notes a wider‑than‑expected Q2 loss of $1.05 per share and a miss of analyst estimates, alongside analyst support from HC Wainwright who maintains a $58 price target and a Buy rating. The company’s pipeline focus on late‑stage diabetic macular edema and other ocular therapies, including recent patient enrollment, remains a key theme.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Kodiak Sciences Inc. News trend score: 80. Reason: 7 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
31
🎯 Conviction (vs. Emotion)
50
Psychology
36
Fundamentals
46
Technical
6
Valuation
38
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-9%
Market Narrative
45
Fundamental Reality
50
Narrative Gap
-5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s extreme anchoring (90) suggests traders are fixated on the 0.5% support level, likely due to its proximity. Herding (61) indicates peers’ underperformance may be driving alignment, while muted FOMO (11) and panic (31) imply restrained emotional extremes. The narrative gap (-3) hints at slight overestimation of positive narratives relative to fundamentals. The key question: will traders break the anchor if support holds, or will proximity alone sustain anchoring?
Updated: 09/08/2026, 01:25 PM
What could change this?
👥 What the crowd believes
"now sits within months of three separate Phase 3 readouts"
"First patients enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema"
"HC Wainwright & Co. reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target"
"Begins late-stage study of KSI-501 in Diabetic Macular Edema"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between macro resilience and fundamental caution. At the top of the spectrum, Bagehot and Nelson see it as a liquidity-rich or cyclically oversold opportunity, praising its ability to weather stress or its undervalued position in a broader market cycle. Schwager and Mackay also lean bullish, emphasizing disciplined setups and the absence of speculative mania. However, the middle tier—particularly Howard Marks—introduces nuance, warning that while the timing may be favorable, the stock’s valuation could already reflect high expectations. Meanwhile, Graham’s strict criteria and the efficient-market camp dismiss it outright, with the latter arguing passive indexing is the rational default. The bottom half, from Livermore’s trend aversion to Lynch’s lack of growth data, suggests either structural weakness or a mismatch for active, growth-focused, or patient investing styles, painting a picture of a stock that excites some but fails to meet the rigorous standards of others.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 97
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 80
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 79
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 62
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 54
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 27
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 23
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 0
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-146.1%
ROA
-65.4%
ROIC
—
EPS
-$4.32
Cash
$209.86M
Total Debt
—
Current Ratio
4.72
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$32.71
Estimated Fair Value (DCF)
-$47.86
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-246.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-150.17M | $-137.77M |
| 2 | 8.1% | $-162.37M | $-136.66M |
| 3 | 6.3% | $-172.51M | $-133.21M |
| 4 | 4.4% | $-180.06M | $-127.56M |
| 5 | 2.5% | $-184.56M | $-119.95M |
Base FCF (last actual year)
$-136.51M
Terminal Value
$-2.91B
Present Value of Terminal Value
$-1.89B
Enterprise Value
$-2.55B
Net Debt
$0
Equity Value
$-2.55B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.96
Tangible Book Value per Share (Tangible NAV)
$2.96
Sentiment based on basic keywords (not AI) — 7 positive, 11 neutral, 2 negative out of the last 20 articles.
SeekingAlpha · 19.9.2026
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 13.9.2026
Yahoo · 3.9.2026
Insider Monkey · 3.9.2026
Benzinga · 25.8.2026
Benzinga · 17.8.2026
Zacks · 14.8.2026
PR Newswire · 13.8.2026
Benzinga · 13.8.2026
Zacks · 11.8.2026
MT Newswires · 10.8.2026
PR Newswire · 10.8.2026
Benzinga · 10.8.2026
PR Newswire · 6.8.2026
Benzinga · 3.8.2026
Motley Fool · 10.6.2026
Simply Wall St. · 6.6.2026
Kodiak Sciences Inc (KOD) currently has a StockIQ AI score of 35/100, rated "Weak" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
KOD currently scores 35/100 (Weak) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, KOD's estimated fair value is -$47.86, which is 246.3% below the current price of $32.71. This is one valuation model among several signals in the fair-value category, not a price target.
KOD's technical score is 6/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 4.72; Current ratio: 4.72.
Based on the real signals StockIQ computed: Estimated fair value: -$47.86 vs. price $32.71 (-246.3%); ATR: 5.8% of price; Return on equity (ROE): -146.1% (negative).
StockIQ has no recorded dividend payment history for KOD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| PERLROTH VICTOR | Grant/Award from Employer | 15.7.2026 | 100,000 | +100,000 | — |
| BORGESON JOHN A. | Grant/Award from Employer | 15.7.2026 | 66,500 | +66,500 | — |
| BORGESON JOHN A. | Grant/Award from Employer | 15.7.2026 | 66,500 | +66,500 | — |
| PERLROTH VICTOR | Grant/Award from Employer | 15.7.2026 | 100,000 | +100,000 | — |
| BAKER BROS. ADVISORS LP | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Dahiyat Bassil I | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Levy Richard S | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Yang Taiyin | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| PROFUSEK ROBERT | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Bancroft Charles A | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| BAKER BROS. ADVISORS LP | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| BAKER BROS. ADVISORS LP | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| PROFUSEK ROBERT | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Yang Taiyin | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Levy Richard S | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Bancroft Charles A | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| Dahiyat Bassil I | Grant/Award from Employer | 30.6.2026 | 17,731 | +17,731 | — |
| BORGESON JOHN A. | Open Market Sale | 4.6.2026 | 4,104 | -4,104 | $34.67 |
| BORGESON JOHN A. | Open Market Sale | 4.6.2026 | 25,896 | -25,896 | $34.01 |
| BORGESON JOHN A. | Exercise of Derivative Securities | 4.6.2026 | 30,000 | -30,000 | — |
| BORGESON JOHN A. | Exercise of Derivative Securities | 4.6.2026 | 30,000 | +30,000 | $1.04 |
| BORGESON JOHN A. | Exercise of Derivative Securities | 4.6.2026 | 241,930 | +30,000 | $1.04 |
| BORGESON JOHN A. | Open Market Sale | 4.6.2026 | 216,034 | -25,896 | $34.01 |
| BORGESON JOHN A. | Open Market Sale | 4.6.2026 | 211,930 | -4,104 | $34.67 |
| BORGESON JOHN A. | Exercise of Derivative Securities | 4.6.2026 | 0 | -30,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
10,780,926 shares short as of 2026-08-31 · vs. 10,229,369 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
62.2% of trading volume this week was short selling, vs. 56.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology